Twist Bioscience Shares Fall Following Weak Fiscal 2027 Guidance Despite Q4 Revenue Beat
Twist Bioscience (TWST) experienced a sharp decline in premarket trading following the release of its fourth-quarter fiscal 2026 results. While the synthetic biology company exceeded Wall Street revenue expectations by reporting $126.6 million for the quarter, investor sentiment was dampened by the firm's forward-looking projections. The primary driver for the stock's decline was an underwhelming guidance forecast for fiscal year 2027. Despite the immediate quarterly beat, the market reacted negatively to the company's long-term outlook, suggesting potential headwinds or slower growth expectations in the coming fiscal periods.
Tickers: $TWST
Topics: earnings report guidance miss revenue beat stock price movement